Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms (Q44912928)

7 December 2017

title

Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms (English)

1 reference

7 December 2017

1 reference

6

1 reference

7 December 2017

Anna Melissa Schlitter

series ordinal

2

object named as

Anna Melissa Schlitter

1 reference

7 December 2017

5

Irene Esposito

1 reference

7 December 2017

7

Özlem Türeci

1 reference

7 December 2017

3

Karl Dhaene

1 reference

7 December 2017

1

Stefan Wöll

1 reference

7 December 2017

Marc Roller

4

1 reference

7 December 2017

language of work or name

English

0 references

publication date

16 September 2013

1 reference

International Journal of Cancer

7 December 2017

published in

1 reference

7 December 2017

volume

134

1 reference

7 December 2017

issue

3

1 reference

7 December 2017

page(s)

731-739

1 reference

Estimates of cancer incidence and mortality in Europe in 2008.

7 December 2017

cites work

1 reference

21 January 2018

Global cancer statistics

1 reference

Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

Global estimates of cancer prevalence for 27 sites in the adult population in 2008.

21 January 2018

1 reference

EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary.

21 January 2018

1 reference

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

21 January 2018

1 reference

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).

21 January 2018

1 reference

Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium

21 January 2018

1 reference

Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205

21 January 2018

1 reference

Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer

21 January 2018

1 reference

Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development

21 January 2018

1 reference

Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals

21 January 2018

1 reference

New markers of pancreatic cancer identified through differential gene expression analyses: claudin 18 and annexin A8.

21 January 2018

1 reference

Claudin-18 is an early-stage marker of pancreatic carcinogenesis

21 January 2018

1 reference

An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers

21 January 2018

1 reference

claudin-18, a novel downstream target gene for the T/EBP/NKX2.1 homeodomain transcription factor, encodes lung- and stomach-specific isoforms through alternative splicing

21 January 2018

1 reference

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

The emerging role of MET/HGF inhibitors in oncology

21 January 2018

1 reference

Transcriptional regulation of claudin-18 via specific protein kinase C signaling pathways and modification of DNA methylation in human pancreatic cancer cells

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.28400

1 reference

7 December 2017

1 reference